1.678USD+0.48%Mkt Cap: 16.69M USDP/E: —Last update: 2026-05-26
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lea…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap16.69M USD
Enterprise Value-3.04M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-19.44M USD
Revenue/Share—
Last Price1.678 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.58
PEG—
EV/EBITDA0.17
EV/Revenue—
P/S—
P/B0.73
EPS (TTM)-2.54
EPS (Forward)-1.06
52W Range
1.17011% of range5.610
52W High5.610 USD
52W Low1.170 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-70.54%
ROA-60.22%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.71M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-42.71%
Net Debt-19.59M USD
Net Debt/EBITDA1.10
Balance Sheet
Debt/Equity0.10
Current Ratio10.50
Quick Ratio10.17
Book Value/Sh2.313 USD
Cash/Share2.228 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateJun 6, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)6.250 USD
Target Range4.000 USD – 10.00 USD
# Analysts4
Ownership
Shares Out.9.85M
Float7.03M
Insiders20.79%
Institutions38.12%
Short Interest
Short Ratio4.0d
Short % Float2.79%
Short % Out.2.49%
Shares Short245.61K
Short (prev mo.)296.11K
Technical
SMA 501.556 (+7.8%)
SMA 2001.892 (-11.3%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)66.28K
Avg Vol (10d)64.70K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—